MiSight parameters extended

Positive Impact

Positive Impact (PI) has announced a new collaboration with Lumenis BE, the inventor of intense pulsed light technology. PI will now provide professional support, education and clinical training in the UK for OptiLight – said to be the first and only light treatment FDA-approved for the management of dry eye disease due to meibomian gland dysfunction with its patented Optimal Pulse Technology.

The companies believe that independent practices can expand their business with OptiLight, offering a new line of treatment for dry eye and a possible upgrade to aesthetic skin treatments.

EMEA Lumenis Vision sales director, Paris Hatzianastasiadis, said: “We are delighted to introduce OptiLight to the UK market and offer a root-cause treatment that elevates dry eye management. With our one-of-a-kind technology, and Positive Impact’s experienced team to support our activities on the ground in the UK, we can improve health and quality of life for dry eye patients.”

PI managing director, Nick Atkins, added: “OptiLight fits perfectly with our business ethos of only working with best-in-class products that offer differentiation and generate sales for the independent practice. I have long felt that the future of successful dry eye management, both clinically and commercially, lies with professional in-practice treatment options.”

International Eyewear

From contemporary classics to traditional favourites, Puccini Eyewear from International Eyewear is designed to embody modest elegance: a collection of timeless styles embracing the beauty in simplicity with noteworthy eyeshapes and inspiring detailing. Comfort is at the forefront of the frame designs, without compromising on understated style, with considered features including silicone nose pads as standard.

Elegant new models Puccini 318 and Puccini 319 showcase a stainless steel eye front, coupled with handmade acetate sides featuring tonal colour block temple laminations in a delicate, feminine colour palette. This timeless design is available in supra (PC319) and petite (PC318) styles with additional considered comfort features.

Modest elegance for a feminine look

Stepper

The Stepper SI-20119

The new SI-20119 style from Stepper features both TX5 plastic and titanium, offering “the perfect combination for eyewear that’s fit for purpose”, says Stepper managing director, Peter Reeve. The frame’s TX5 and titanium elements offer both weight and skin allergy benefits. The TX5 front is moulded into its final form, including facial contour design and the renown Stepper bridge, creating a frame that “works in harmony with the wearer’s anatomy”. Svelte titanium sides offer rigidity and strength, holding the frame securely in place. The SI-20119 is available in smoke, grey-blue mottle and blue in size 54-17.

CooperVision

CooperVision has expanded the parameters for MiSight 1 day contact lenses to cover -0.25D to -10.00D (0.50D steps after -6.00D). This means the lens covers 99.97 per cent of prescriptions for Asian children and 99.97 per cent for Caucasian children who have myopia and less than 1.00D of astigmatism, said the company.

MiSight 1 day contact lenses are backed by the longest-running soft contact lens study among children. The trial has, according to CooperVision, proven that MiSight 1 day works for nearly all children with myopia, cuts the worsening of myopia by half, works at any age a child starts treatment (aged eight plus), works for as long as the child wears them, and that myopia management benefits from MiSight 1 day are retained after treatment.

“Every dioptre matters, particularly for children whose worsening myopia may have already placed them at a higher risk

Every dioptre matters

for conditions such as myopic maculopathy and glaucoma,” said Elizabeth Lumb, CooperVision director of global professional affairs, myopia management. “While early treatment is best, it’s never too late to start. Even older children starting with MiSight® 1 day have seen the worsening of their myopia cut by half”.

SUMMER 2022 COLLECTION NOW AVAILABLE